OSR Holdings, Inc. operates as a blank check company. The company is headquartered in Bellevue, Washington. The company went IPO on 2023-02-10. The firm is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The firm's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The firm has operations in Europe and South Korea.
How did OSRH's recent EPS compare to expectations?
The most recent EPS for OSR Holdings Inc is $-0.16, beating expectations of $-0.1.
How did OSR Holdings Inc OSRH's revenue perform in the last quarter?
OSR Holdings Inc revenue for the last quarter is $-0.16
What is the revenue estimate for OSR Holdings Inc?
According to 3 of Wall street analyst, the revenue estimate of OSR Holdings Inc range from $816.9K to $762.44K
What's the earning quality score for OSR Holdings Inc?
OSR Holdings Inc has a earning quality score of B+/46.2592. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does OSR Holdings Inc report earnings?
OSR Holdings Inc next earnings report is expected in 2026-06-29
What are OSR Holdings Inc's expected earnings?
OSR Holdings Inc expected earnings is $776.22K, according to wall-street analysts.
Did OSR Holdings Inc beat earnings expectations?
OSR Holdings Inc recent earnings of $381.27K does not beat expectations.